Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][3] - The company's lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments, including several DNA Damage Response (DDR) pathways [3] Upcoming Events - Daniel Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference 2025 on May 8, 2025, at 12:30 PM ET [1][2] - The presentation will be accessible via a webcast on the Actuate website, and the management team will participate in one-on-one investor meetings during the event [2]
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025